Eisai 和 Biogen 研發的阿爾茨海默症藥物在大型試驗中顯示減緩病情發展

智通財經
2022.09.28 01:15
Eisai Co.和合作夥伴 Biogen Inc.表示，他們研發的阿爾茨海默症治療藥物 lecanemab 減緩了這種疾病的發展，成為第一款在最後階段試驗中明顯抑制阿爾茨海默症發展的藥物。據兩家公司發佈的聲明，與使用共同評級量表的安慰劑相比，這款藥物在 18 個月內使早期阿爾茨海默症患者的認知下降速度減緩了 27％，達到了試驗的主要目標。雖然作用影響温和，但達到高度統計學顯著性。
Source: 智通財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.